Weak D Testing is not Required for D− Patients With C−E− Phenotype.
10.3343/alm.2018.38.6.585
- Author:
Sooin CHOI
1
;
Sejong CHUN
;
Hwan Tae LEE
;
HongBi YU
;
Ji Young SEO
;
Duck CHO
Author Information
1. Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. duck.cho@skku.edu
- Publication Type:Original Article
- Keywords:
C−E− phenotype;
Weak D testing;
RHD genotyping;
RhD blood type;
Algorithm;
D typing;
Cost effectiveness;
Testing time
- MeSH:
Cost-Benefit Analysis;
Humans;
Korea;
Phenotype*;
Retrospective Studies;
Tertiary Care Centers
- From:Annals of Laboratory Medicine
2018;38(6):585-590
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Although testing to detect weak D antigens using the antihuman globulin reagent is not required for D− patients in many countries, it is routinely performed in Korea. However, weak D testing can be omitted in D− patients with a C−E− phenotype as this indicates complete deletion of the RHD gene, except in rare cases. We designed a new algorithm for weak D testing, which consisted of RhCE phenotyping followed by weak D testing in C+ or E+ samples, and compared it with the current algorithm with respect to time and cost-effectiveness. METHODS: In this retrospective study, 74,889 test results from January to July 2017 in a tertiary hospital in Korea were analyzed. Agreement between the current and proposed algorithms was evaluated, and total number of tests, time required for testing, and test costs were compared. With both algorithms, RHD genotyping was conducted for samples that were C+ or E+ and negative for weak D testing. RESULTS: The algorithms showed perfect agreement (agreement=100%; κ=1.00). By applying the proposed algorithm, 29.56% (115/389 tests/yr) of tests could be omitted, time required for testing could be reduced by 36% (8,672/24,084 min/yr), and the test cost could be reduced by 16.53% (536.11/3,241.08 USD/yr). CONCLUSIONS: Our algorithm omitting weak D testing in D− patients with C−E− phenotype may be a cost-effective testing strategy in Korea.
